Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533719 | 1.00 | HRH3 (0.37) | HRH3LMNAKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL14417314 | 0.90 | NPSR1 (0.43) | LMNAKMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5519865 | 0.84 | NPSR1 (0.44) | LMNAKMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5525096 | 0.84 | ACKR3 (0.40) | SMN1; SMN2KDM4EALDH1A1GAACYP2C9 | |
| SCHEMBL14417315 | 0.84 | NPSR1 (0.44) | LMNAKMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5525549 | 0.74 | DHODH (0.40) | KDM4EMAPTPOLB | |
| SCHEMBL5519869 | 0.74 | KDM4E (0.41) | HRH3LMNAKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL5709770 | 0.72 | CES2 (0.31) | — | |
| SCHEMBL5709771 | 0.72 | CES2 (0.31) | — | |
| SCHEMBL5525554 | 0.67 | ACKR3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | TP53, RB1, HRAS | HRH3 494/4885LMNA 1366/4885KMT2A 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.